Impact of genetic variants of selected cytochrome P450 isoenzymes on pharmacokinetics and pharmacodynamics of clopidogrel in patients co-treated with atorvastatin or rosuvastatin.
Marta Karaźniewicz-ŁadaDagmara KrzyżańskaDorota DanielakJanusz RzeźniczakFranciszek GłówkaMarek SłomczyńskiPaweł BurchardtPublished in: European journal of clinical pharmacology (2020)
The CYP2C19*2 allele is the primary determinant of the exposition to the H4 active metabolite of clopidogrel and platelet reactivity in patients co-treated with atorvastatin or rosuvastatin.